Table 3 Adverse events regardless of study-drug relationship in ≥10 % of patients in either treatment group. Adverse events are reported from extension baseline up to month 26
Crossed over to pasireotide LAR (N = 81) | Crossed over to octreotide LAR (N = 38) | |||
|---|---|---|---|---|
Adverse event | All grades n (%) | Grade 3/4 n (%) | All grades n (%) | Grade 3/4 n (%) |
Total | 75 (92.6) | 19 (23.5) | 34 (89.5) | 8 (21.1) |
Hyperglycemia | 22 (27.2) | 4 (4.9) | 5 (13.2) | 0 |
Diarrhea | 18 (22.2) | 0 | 7 (18.4) | 1 (2.6) |
Cholelithiasis | 15 (18.5) | 1 (1.2) | 6 (15.8) | 1 (2.6) |
Headache | 16 (19.8) | 0 | 5 (13.2) | 0 |
Diabetes mellitus | 15 (18.5) | 1 (1.2) | 3 (7.9) | 0 |
Nasopharyngitis | 12 (14.8) | 0 | 7 (18.4) | 0 |
Arthralgia | 10 (12.3) | 0 | 2 (5.3) | 0 |
Increased blood creatine phosphokinase | 6 (7.4) | 0 | 6 (15.8) | 0 |
Dizziness | 5 (6.2) | 0 | 5 (13.2) | 0 |
Increased blood triglycerides | 1 (1.2) | 0 | 4 (10.5) | 1 (2.6) |